Jump to content
Powered by

Pharmaceutics

The latest articles, press releases and dossiers on pharmaceutics in Baden-Württemberg

  • Article - 09/03/2015

    High fever, chills, cramps and severe anaemia are typical symptoms of malaria, even its mild form. According to World Health Organisation (WHO) estimates, around 660,000 people die from malaria every year. The disease is transmitted by female Anopheles mosquitoes infected by single-celled parasites of the genus Plasmodium. Malaria is difficult to treat or cure as it is caused by a eukaryotic organism that is biochemically more similar to humans…

  • Article - 09/03/2015

    Vaccines that prevent infection with cancer-causing viruses are already available. Moreover, the development of therapeutic vaccines for the treatment of a number of other cancers is well under way. These vaccines not only prevent the development of cancer, but also treat early stages of cancer. Antigen-armed antibodies have long been used in vaccines against infectious diseases, and can now also be used for treating cancer.

  • Press release - 06/03/2015

    The Bill & Melinda Gates Foundation and CureVac announced that the foundation has made a commitment to invest €46 million in CureVac, a leading clinical-stage biopharmaceutical company specializing in mRNA-based vaccine technologies. As part of the agreement, the foundation will also provide separate funding for several projects to develop prophylactic vaccines based on CureVac’s proprietary messenger RNA platform. In addition, CureVac’s…

  • Article - 16/02/2015

    The bacterium Vibrio cholerae causes cholera, a severe disease that affects up to 3.5 million people a year. A team of scientists from the universities of Freiburg, Hohenheim and Konstanz have now gained new insights into the way the bacterium produces energy. They have elucidated the structure and function of the bacterium’s energy-production machinery. The research results provide new insights into biochemical energy production and the…

  • Article - 16/02/2015

    Therapeutic cancer vaccines have the potential to boost the immune system's ability to destroy tumour cells. Cancer researchers around the world are intensively studying the potential of this therapeutic concept and initial positive results have been obtained. Cancer researchers from Heidelberg have developed a vaccine that triggers an immune response against a protein that is mutated in brain cancer. The vaccine, which successfully arrested…

  • Dossier - 09/02/2015

    The boundaries between traditional scientific disciplines are becoming less and less distinct. Interdisciplinary cooperation is often required to study complex processes and biomolecular issues. Interdisciplinary cooperation is central to chemical biology, a scientific discipline that applies chemical substances, methods and tools to the study of biological systems ranging from the chemical synthesis of biologically active substances to the…

  • Article - 09/02/2015

    No cancer therapy is currently achieving such promising results as immunotherapy. The German Cancer Research Center and Bayer HealthCare have established a joint laboratory to develop novel immunotherapies that selectively reactivate the body’s own immune system and incite it to attack tumour cells, thereby supporting the faster translation of concepts from the laboratory into clinical application.

  • Article - 02/02/2015

    The Laupheim-based contract manufacturer Rentschler Biotechnologie GmbH is greatly expanding its production capacities. The company is investing €24 million in the construction of two 3,000 litre stainless steel bioreactors, which should be operational in early 2017 and will more than double the production capacities for cell culture-derived proteins. Rentschler also announced recently that it was adding a new 2,000 litre single-use bioreactor…

  • Article - 26/01/2015

    Over 150 scientists at various locations throughout Germany work together as part of the German Centre for Infection Research (DZIF). The centre focuses on the development of new diagnostic, preventive and therapeutic methods for treating infectious diseases. Scientists from the University and University Hospital of Tübingen and the Max Planck Institute for Developmental Biology are also part of the project. The researchers from Tübingen are…

  • Press release - 08/01/2015

    BioRN is a member of the consortium InnoLife, which has won the call for the Knowledge and Innovation Community (KIC) Healthy Living and Active Ageing (EIT Health) of the European Institute for Innovation and Technology (EIT). With a grant volume of up to 700 million euros and a total project volume of more than 2 billion euros, this is one of the largest publicly funded initiatives in the health sector worldwide.

  • Article - 22/12/2014

    Virologist Prof. Dr. Stephan Urban from the University of Heidelberg has been awarded the DZIF Prize for Translational Infection Research for the discovery and development of a promising peptide drug for the treatment of hepatitis B virus infections. The peptide prevents viruses from entering the liver cells, and is also effective against hepatitis D infection. Hepatitis D is the deadliest of all viral liver diseases and no specific antiviral…

  • Article - 22/12/2014

    The ability to recognise a pathogen and combat it effectively is certainly one of the most complex and sophisticated processes the human body has evolved. People with an immunodeficiency or autoimmune disease may have a genetic defect in one of the genes involved in the immune response. Working with immunologists from London, scientists Desirée Schubert and Prof. Dr. Bodo Grimbacher from the Centre for Chronic Immunodeficiency (CCI) at the…

Website address: https://www.gesundheitsindustrie-bw.de/en/article/pharma